The use of platelet-rich plasma in bone reconstruction therapy

Biomaterials

Volumn 30, Issue 28, 2009, Pages 4956-4966

  Intini, Giuseppe ^a  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

Bone reconstruction therapy; Bone regeneration; Dental surgery; Growth factors; Orthopaedic surgery; Platelet rich plasma

Indexed keywords

BONE RECONSTRUCTION THERAPY; BONE REGENERATION; DENTAL SURGERY; GROWTH FACTORS; ORTHOPAEDIC SURGERY; PLATELET-RICH PLASMA;

BIOACTIVITY; BLOOD SUBSTITUTES; DENTISTRY; ORTHOPEDICS; PEPTIDES; PLASMAS; PLATELETS; REPAIR; SURGERY;

BONE;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANGIOPOIETIN 2; BASIC FIBROBLAST GROWTH FACTOR; BETA THROMBOGLOBULIN; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; CALCIUM PHOSPHATE; EPIDERMAL GROWTH FACTOR; FIBRINOGEN; FIBROBLAST GROWTH FACTOR 2; HYDROXYAPATITE; OSTEOCALCIN; PADGEM PROTEIN; PLACEBO; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT BONE MORPHOGENETIC PROTEIN 4; RECOMBINANT PROTEIN; RECOMBINANT VASCULOTROPIN; SEROTONIN; SOMATOMEDIN C; THROMBIN; THROMBOSPONDIN 1; THYMIDINE PHOSPHORYLASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ALVEOLAR BONE; BONE DEFECT; BONE DISEASE; BONE REGENERATION; BONE REMODELING; CANCELLOUS BONE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FRACTURE HEALING; HUMAN; NONHUMAN; ORTHOPEDIC SURGERY; OSTEOBLAST; OSTEOLYSIS; PERIODONTAL DISEASE; PLASTIC SURGERY; PRIORITY JOURNAL; PROTEIN FUNCTION; REGENERATIVE MEDICINE; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE RICH PLASMA; TISSUE ENGINEERING; TRABECULAR BONE;

ANIMALS; BLOOD PLATELETS; BONE REGENERATION; HUMANS; ORAL SURGICAL PROCEDURES; ORTHOPEDIC PROCEDURES; PLATELET-DERIVED GROWTH FACTOR; PLATELET-RICH PLASMA; RECONSTRUCTIVE SURGICAL PROCEDURES;

EID: 67849101635     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.05.055     Document Type: Review

References (144)

1. Wang E.A., Rosen V., D'Alessandro J.S., Bauduy M., Cordes P., Harada T., et al. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci U S A 87 6 (1990) 2220-2224
2. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., et al. Novel regulators of bone formation: molecular clones and activities. Science 242 4885 (1988) 1528-1534
3. Govender S., Csimma C., Genant H.K., Valentin-Opran A., Amit Y., Arbel R., et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84-A 12 (2002) 2123-2134
4. Szpalski M., and Gunzburg R. Recombinant human bone morphogenetic protein-2: a novel osteoinductive alternative to autogenous bone graft?. Acta Orthop Belg 71 2 (2005) 133-148
5. Termaat M.F., Den Boer F.C., Bakker F.C., Patka P., and Haarman H.J. Bone morphogenetic proteins. Development and clinical efficacy in the treatment of fractures and bone defects. J Bone Joint Surg Am 87 6 (2005) 1367-1378
6. Kumar V., Cotran R.S., and Robbins S.L. Tissue repair: cell regeneration and fibrosis. Basic pathology. 7th ed. (2003), Saunders, Philadelphia p. 61-78
7. Gerstenfeld L.C., Cullinane D.M., Barnes G.L., Graves D.T., and Einhorn T.A. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem 88 5 (2003) 873-884
8. Marx R.E., Carlson E.R., Eichstaedt R.M., Schimmele S.R., Strauss J.E., and Georgeff K.R. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 85 6 (1998) 638-646
9. Marx R.E. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg 62 4 (2004) 489-496
10. Freymiller E.G., and Aghaloo T.L. Platelet-rich plasma: ready or not?. J Oral Maxillofac Surg 62 4 (2004) 484-488
11. Frechette J.P., Martineau I., and Gagnon G. Platelet-rich plasmas: growth factor content and roles in wound healing. J Dent Res 84 5 (2005) 434-439
12. Lacoste E., Martineau I., and Gagnon G. Platelet concentrates: effects of calcium and thrombin on endothelial cell proliferation and growth factor release. J Periodontol 74 10 (2003) 1498-1507
13. Hoffman R., Benz E.J.J., Shattil S.J., Furie B., Cohen H.J., Silberstein L.E., et al. Hematology: basic principles and practice (2000), Churchill Livingstone, Philadelphia
14. Thiede M.A., Smock S.L., Petersen D.N., Grasser W.A., Thompson D.D., and Nishimoto S.K. Presence of messenger ribonucleic acid encoding osteocalcin, a marker of bone turnover, in bone marrow megakaryocytes and peripheral blood platelets. Endocrinology 135 3 (1994) 929-937
15. Hoebertz A., Arnett T.R., and Burnstock G. Regulation of bone resorption and formation by purines and pyrimidines. Trends Pharmacol Sci 24 6 (2003) 290-297
16. Morrison M.S., Turin L., King B.F., Burnstock G., and Arnett T.R. ATP is a potent stimulator of the activation and formation of rodent osteoclasts. J Physiol 511 Pt 2 (1998) 495-500
17. Hoebertz A., Meghji S., Burnstock G., and Arnett T.R. Extracellular ADP is a powerful osteolytic agent: evidence for signaling through the P2Y(1) receptor on bone cells. FASEB J 15 7 (2001) 1139-1148
18. Werner S., and Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 83 3 (2003) 835-870
19. Kampfer H., Pfeilschifter J., and Frank S. Expressional regulation of angiopoietin-1 and -2 and the tie-1 and -2 receptor tyrosine kinases during cutaneous wound healing: a comparative study of normal and impaired repair. Lab Invest 81 3 (2001) 361-373
20. Castor C.W., Miller J.W., and Walz D.A. Structural and biological characteristics of connective tissue activating peptide (CTAP-III), a major human platelet-derived growth factor. Proc Natl Acad Sci U S A 80 3 (1983) 765-769
21. Deutsch V., Bitan M., Friedmann Y., Eldor A., and Vlodavsky I. Megakaryocyte maturation is associated with expression of the CXC chemokine connective tissue-activating peptide CTAP III. Br J Haematol 111 4 (2000) 1180-1189
22. Han Z.C., Lu M., Li J., Defard M., Boval B., Schlegel N., et al. Platelet factor 4 and other CXC chemokines support the survival of normal hematopoietic cells and reduce the chemosensitivity of cells to cytotoxic agents. Blood 89 7 (1997) 2328-2335
23. Steed D.L. Modifying the wound healing response with exogenous growth factors. Clin Plast Surg 25 3 (1998) 397-405
24. Grayson L.S., Hansbrough J.F., Zapata-Sirvent R.L., Dore C.A., Morgan J.L., and Nicolson M.A. Quantitation of cytokine levels in skin graft donor site wound fluid. Burns 19 5 (1993) 401-405
25. Marie P.J., Hott M., and Perheentupa J. Effects of epidermal growth factor on bone formation and resorption in vivo. Am J Physiol 258 2 Pt 1 (1990) E275-E281
26. Wang K., Yamamoto H., Chin J.R., Werb Z., and Vu T.H. Epidermal growth factor receptor-deficient mice have delayed primary endochondral ossification because of defective osteoclast recruitment. J Biol Chem 279 51 (2004) 53848-53856
27. Claes L., Burri C., Gerngross H., and Mutschler W. Bone healing stimulated by plasma factor XIII. Osteotomy experiments in sheep. Acta Orthop Scand 56 1 (1985) 57-62
28. Ortega S., Ittmann M., Tsang S.H., Ehrlich M., and Basilico C. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. Proc Natl Acad Sci U S A 95 10 (1998) 5672-5677
29. Miller D.L., Ortega S., Bashayan O., Basch R., and Basilico C. Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice. Mol Cell Biol 20 6 (2000) 2260-2268
30. Fujita M., Kinoshita Y., Sato E., Maeda H., Ozono S., Negishi H., et al. Proliferation and differentiation of rat bone marrow stromal cells on poly(glycolic acid)-collagen sponge. Tissue Eng 11 9-10 (2005) 1346-1355
31. Dupree M.A., Pollack S.R., Levine E.M., and Laurencin C.T. Fibroblast growth factor 2 induced proliferation in osteoblasts and bone marrow stromal cells: a whole cell model. Biophys J 91 8 (2006) 3097-3112
32. Komaki H., Tanaka T., Chazono M., and Kikuchi T. Repair of segmental bone defects in rabbit tibiae using a complex of beta-tricalcium phosphate, type I collagen, and fibroblast growth factor-2. Biomaterials 27 29 (2006) 5118-5126
33. Hosokawa R., Kikuzaki K., Kimoto T., Matsuura T., Chiba D., Wadamoto M., et al. Controlled local application of basic fibroblast growth factor (FGF-2) accelerates the healing of GBR. An experimental study in beagle dogs. Clin Oral Implants Res 11 4 (2000) 345-353
34. Takayama S., Murakami S., Shimabukuro Y., Kitamura M., and Okada H. Periodontal regeneration by FGF-2 (bFGF) in primate models. J Dent Res 80 12 (2001) 2075-2079
35. Damsky C.H. Extracellular matrix-integrin interactions in osteoblast function and tissue remodeling. Bone 25 1 (1999) 95-96
36. Garcia A.J., and Reyes C.D. Bio-adhesive surfaces to promote osteoblast differentiation and bone formation. J Dent Res 84 5 (2005) 407-413
37. Weiss R.E., and Reddi A.H. Role of fibronectin in collagenous matrix-induced mesenchymal cell proliferation and differentiation in vivo. Exp Cell Res 133 2 (1981) 247-254
38. Moursi A.M., Damsky C.H., Lull J., Zimmerman D., Doty S.B., Aota S., et al. Fibronectin regulates calvarial osteoblast differentiation. J Cell Sci 109 Pt 6 (1996) 1369-1380
39. Zimmerman D., Jin F., Leboy P., Hardy S., and Damsky C. Impaired bone formation in transgenic mice resulting from altered integrin function in osteoblasts. Dev Biol 220 1 (2000) 2-15
40. Han D.K., Kim C.S., Jung U.W., Chai J.K., Choi S.H., Kim C.K., et al. Effect of a fibrin-fibronectin sealing system as a carrier for recombinant human bone morphogenetic protein-4 on bone formation in rat calvarial defects. J Periodontol 76 12 (2005) 2216-2222
41. Schaffner P., and Dard M.M. Structure and function of RGD peptides involved in bone biology. Cell Mol Life Sci 60 1 (2003) 119-132
42. Pierschbacher M., Hayman E.G., and Ruoslahti E. Synthetic peptide with cell attachment activity of fibronectin. Proc Natl Acad Sci U S A 80 5 (1983) 1224-1227
43. Werner H., and Katz J. The emerging role of the insulin-like growth factors in oral biology. J Dent Res 83 11 (2004) 832-836
44. Trippel S.B. Potential role of insulinlike growth factors in fracture healing. Clin Orthop Related Res 355 Suppl. (1998) S301-S313
45. Conover C.A. In vitro studies of insulin-like growth factor I and bone. Growth Horm IGF Res 10 Suppl. B (2000) S107-S110
46. Canalis E. Effect of insulinlike growth factor I on DNA and protein synthesis in cultured rat calvaria. J Clin Invest 66 4 (1980) 709-719
47. Tanaka H., Quarto R., Williams S., Barnes J., and Liang C.T. In vivo and in vitro effects of insulin-like growth factor-I (IGF-I) on femoral mRNA expression in old rats. Bone 15 6 (1994) 647-653
48. Barnes G.L., Kostenuik P.J., Gerstenfeld L.C., and Einhorn T.A. Growth factor regulation of fracture repair. J Bone Miner Res 14 11 (1999) 1805-1815
49. Dimitriou R., Tsiridis E., and Giannoudis P.V. Current concepts of molecular aspects of bone healing. Injury 36 12 (2005) 1392-1404
50. Chen F.M., Zhao Y.M., Wu H., Deng Z.H., Wang Q.T., Zhou W., et al. Enhancement of periodontal tissue regeneration by locally controlled delivery of insulin-like growth factor-I from dextran-co-gelatin microspheres. J Control Release 114 2 (2006) 209-222
51. Giannobile W.V., Finkelman R.D., and Lynch S.E. Comparison of canine and non-human primate animal models for periodontal regenerative therapy: results following a single administration of PDGF/IGF-I. J Periodontol 65 12 (1994) 1158-1168
52. Price P.A. Vitamin K-dependent formation of bone Gla protein (osteocalcin) and its function. Vitam Horm 42 (1985) 65-108
53. Hauschka P.V., Lian J.B., Cole D.E., and Gundberg C.M. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69 3 (1989) 990-1047
54. Malone J.D., Teitelbaum S.L., Griffin G.L., Senior R.M., and Kahn A.J. Recruitment of osteoclast precursors by purified bone matrix constituents. J Cell Biol 92 1 (1982) 227-230
55. Epstein S., Poser J., McClintock R., Johnston Jr. C.C., Bryce G., and Hui S. Differences in serum bone GLA protein with age and sex. Lancet 1 8372 (1984) 307-310
56. Johansen J.S., Giwercman A., Hartwell D., Nielsen C.T., Price P.A., Christiansen C., et al. Serum bone Gla-protein as a marker of bone growth in children and adolescents: correlation with age, height, serum insulin-like growth factor I, and serum testosterone. J Clin Endocrinol Metab 67 2 (1988) 273-278
57. Slovik D.M., Gundberg C.M., Neer R.M., and Lian J.B. Clinical evaluation of bone turnover by serum osteocalcin measurements in a hospital setting. J Clin Endocrinol Metab 59 2 (1984) 228-230
58. Lee N.K., Sowa H., Hinoi E., Ferron M., Ahn J.D., Confavreux C., et al. Endocrine regulation of energy metabolism by the skeleton. Cell 130 3 (2007) 456-469
59. Ducy P., Desbois C., Boyce B., Pinero G., Story B., Dunstan C., et al. Increased bone formation in osteocalcin-deficient mice. Nature 382 6590 (1996) 448-452
60. Chen M., and Geng J.G. P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp 54 2 (2006) 75-84
61. Toi M., Atiqur Rahman M., Bando H., and Chow L.W. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 6 3 (2005) 158-166
62. Ishikawa F., Miyazono K., Hellman U., Drexler H., Wernstedt C., Hagiwara K., et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338 6216 (1989) 557-562
63. Raines E.W., and Ross R. Purification of human platelet-derived growth factor. Methods Enzymol 109 (1985) 749-773
64. Ross R. Platelet-derived growth factor. Lancet 1 8648 (1989) 1179-1182
65. Ross R., Raines E.W., and Bowen-Pope D.F. The biology of platelet-derived growth factor. Cell 46 2 (1986) 155-169
66. Alvarez R.H., Kantarjian H.M., and Cortes J.E. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 81 9 (2006) 1241-1257
67. Hsieh S.C., and Graves D.T. Pulse application of platelet-derived growth factor enhances formation of a mineralizing matrix while continuous application is inhibitory. J Cell Biochem 69 2 (1998) 169-180
68. Park Y.J., Lee Y.M., Lee J.Y., Seol Y.J., Chung C.P., and Lee S.J. Controlled release of platelet-derived growth factor-BB from chondroitin sulfate-chitosan sponge for guided bone regeneration. J Control Release 67 2-3 (2000) 385-394
69. Cho M.I., Lin W.L., and Genco R.J. Platelet-derived growth factor-modulated guided tissue regenerative therapy. J Periodontol 66 6 (1995) 522-530
70. Marden L.J., Fan R.S., Pierce G.F., Reddi A.H., and Hollinger J.O. Platelet-derived growth factor inhibits bone regeneration induced by osteogenin, a bone morphogenetic protein, in rat craniotomy defects. J Clin Invest 92 6 (1993) 2897-2905
71. Nevins M., Giannobile W.V., McGuire M.K., Kao R.T., Mellonig J.T., Hinrichs J.E., et al. Platelet-derived growth factor stimulates bone fill and rate of attachment level gain: results of a large multicenter randomized controlled trial. J Periodontol 76 12 (2005) 2205-2215
72. Canalis E., McCarthy T.L., and Centrella M. Effects of platelet-derived growth factor on bone formation in vitro. J Cell Physiol 140 3 (1989) 530-537
73. Hughes F.J., Aubin J.E., and Heersche J.N. Differential chemotactic responses of different populations of fetal rat calvaria cells to platelet-derived growth factor and transforming growth factor beta. Bone Miner 19 1 (1992) 63-74
74. Veenstra-VanderWeele J., Anderson G.M., and Cook Jr. E.H. Pharmacogenetics and the serotonin system: initial studies and future directions. Eur J Pharmacol 410 2-3 (2000) 165-181
75. Lesurtel M., Graf R., Aleil B., Walther D.J., Tian Y., Jochum W., et al. Platelet-derived serotonin mediates liver regeneration. Science 312 5770 (2006) 104-107
76. Matsuda M., Imaoka T., Vomachka A.J., Gudelsky G.A., Hou Z., Mistry M., et al. Serotonin regulates mammary gland development via an autocrine-paracrine loop. Dev Cell 6 2 (2004) 193-203
77. Vitalis T., and Parnavelas J.G. The role of serotonin in early cortical development. Dev Neurosci 25 2-4 (2003) 245-256
78. Westbroek I., van der Plas A., de Rooij K.E., Klein-Nulend J., and Nijweide P.J. Expression of serotonin receptors in bone. J Biol Chem 276 31 (2001) 28961-28968
79. Bliziotes M.M., Eshleman A.J., Zhang X.W., and Wiren K.M. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone 29 5 (2001) 477-486
80. Gustafsson B.I., Thommesen L., Stunes A.K., Tommeras K., Westbroek I., Waldum H.L., et al. Serotonin and fluoxetine modulate bone cell function in vitro. J Cell Biochem 98 1 (2006) 139-151
81. Bliziotes M., Gunness M., Eshleman A., and Wiren K. The role of dopamine and serotonin in regulating bone mass and strength: studies on dopamine and serotonin transporter null mice. J Musculoskelet Neuronal Interact 2 3 (2002) 291-295
82. Massague J., and Gomis R.R. The logic of TGFbeta signaling. FEBS Lett 580 12 (2006) 2811-2820
83. Hollinger J., and Wong M.E. The integrated processes of hard tissue regeneration with special emphasis on fracture healing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 82 6 (1996) 594-606
84. Kingsley D.M. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 8 2 (1994) 133-146
85. Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol 6 (1990) 597-641
86. Alford A.I., and Hankenson K.D. Matricellular proteins: extracellular modulators of bone development, remodeling, and regeneration. Bone 38 6 (2006) 749-757
87. Adams J.C. Thrombospondins: multifunctional regulators of cell interactions. Annu Rev Cell Dev Biol 17 (2001) 25-51
88. Schultz-Cherry S., Chen H., Mosher D.F., Misenheimer T.M., Krutzsch H.C., Roberts D.D., et al. Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J Biol Chem 270 13 (1995) 7304-7310
89. Armstrong L.C., and Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 22 1 (2003) 63-71
90. Neufeld G., Cohen T., Gengrinovitch S., and Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13 1 (1999) 9-22
91. Gale N.W., and Yancopoulos G.D. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 13 9 (1999) 1055-1066
92. Wang Y., Wan C., Deng L., Liu X., Cao X., Gilbert S.R., et al. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest 117 6 (2007) 1616-1626
93. Kleinheinz J., Stratmann U., Joos U., and Wiesmann H.P. VEGF-activated angiogenesis during bone regeneration. J Oral Maxillofac Surg 63 9 (2005) 1310-1316
94. Geiger F., Bertram H., Berger I., Lorenz H., Wall O., Eckhardt C., et al. Vascular endothelial growth factor gene-activated matrix (VEGF165-GAM) enhances osteogenesis and angiogenesis in large segmental bone defects. J Bone Miner Res 20 11 (2005) 2028-2035
95. Kaigler D., Wang Z., Horger K., Mooney D.J., and Krebsbach P.H. VEGF scaffolds enhance angiogenesis and bone regeneration in irradiated osseous defects. J Bone Miner Res 21 5 (2006) 735-744
96. Schmitz J.P., and Hollinger J.O. The biology of platelet-rich plasma. J Oral Maxillofac Surg 59 9 (2001) 1119-1121
97. Dwyer S.D., and Meyers K.M. Anesthetics and anticoagulants used in the preparation of rat platelet-rich-plasma alter rat platelet aggregation. Thromb Res 42 2 (1986) 139-151
98. Choi B.H., Zhu S.J., Kim B.Y., Huh J.Y., Lee S.H., and Jung J.H. Effect of platelet-rich plasma (PRP) concentration on the viability and proliferation of alveolar bone cells: an in vitro study. Int J Oral Maxillofac Surg 34 4 (2005) 420-424
99. Graziani F., Ivanovski S., Cei S., Ducci F., Tonetti M., and Gabriele M. The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. Clin Oral Implants Res 17 2 (2006) 212-219
100. Weibrich G., Hansen T., Kleis W., Buch R., and Hitzler W.E. Effect of platelet concentration in platelet-rich plasma on peri-implant bone regeneration. Bone 34 4 (2004) 665-671
101. Pietrzak W.S., and Eppley B.L. Platelet rich plasma: biology and new technology. J Craniofac Surg 16 6 (2005) 1043-1054
102. Marx R.E. Platelet-rich plasma (PRP): what is PRP and what is not PRP?. Implant Dent 10 4 (2001) 225-228
103. Schlegel K.A., Donath K., Rupprecht S., Falk S., Zimmermann R., Felszeghy E., et al. De novo bone formation using bovine collagen and platelet-rich plasma. Biomaterials 25 23 (2004) 5387-5393
104. Wiltfang J., Kloss F.R., Kessler P., Nkenke E., Schultze-Mosgau S., Zimmermann R., et al. Effects of platelet-rich plasma on bone healing in combination with autogenous bone and bone substitutes in critical-size defects. An animal experiment. Clin Oral Implants Res 15 2 (2004) 187-193
105. Jakse N., Tangl S., Gilli R., Berghold A., Lorenzoni M., Eskici A., et al. Influence of PRP on autogenous sinus grafts. An experimental study on sheep. Clin Oral Implants Res 14 5 (2003) 578-583
106. Dori F., Huszar T., Nikolidakis D., Tihanyi D., Horvath A., Arweiler N.B., et al. Effect of platelet-rich plasma on the healing of intrabony defects treated with beta tricalcium phosphate and expanded polytetrafluoroethylene membranes. J Periodontol 79 4 (2008) 660-669
107. Jensen T.B., Rahbek O., Overgaard S., and Soballe K. Platelet rich plasma and fresh frozen bone allograft as enhancement of implant fixation. An experimental study in dogs. J Orthop Res 22 3 (2004) 653-658
108. Roldan J.C., Jepsen S., Miller J., Freitag S., Rueger D.C., Acil Y., et al. Bone formation in the presence of platelet-rich plasma vs. bone morphogenetic protein-7. Bone 34 1 (2004) 80-90
109. Dolder J.V., Mooren R., Vloon A.P., Stoelinga P.J., and Jansen J.A. Platelet-rich plasma: quantification of growth factor levels and the effect on growth and differentiation of rat bone marrow cells. Tissue Eng (2006)
110. Furst G., Gruber R., Tangl S., Zechner W., Haas R., Mailath G., et al. Sinus grafting with autogenous platelet-rich plasma and bovine hydroxyapatite. A histomorphometric study in minipigs. Clin Oral Implants Res 14 4 (2003) 500-508
111. Sanchez A.R., Sheridan P.J., Eckert S.E., and Weaver A.L. Regenerative potential of platelet-rich plasma added to xenogenic bone grafts in peri-implant defects: a histomorphometric analysis in dogs. J Periodontol 76 10 (2005) 1637-1644
112. Choi B.H., Im C.J., Huh J.Y., Suh J.J., and Lee S.H. Effect of platelet-rich plasma on bone regeneration in autogenous bone graft. Int J Oral Maxillofac Surg 33 1 (2004) 56-59
113. Cummings C.W. Experimental observations of canine mandibular regeneration following segmental removal, freezing, and reimplantation. Ann Otol Rhinol Laryngol Suppl 87 6 Pt 3 Suppl. 54 (1978) 1-11
114. Schmitz J.P., and Hollinger J.O. The critical size defect as an experimental model for craniomandibulofacial nonunions. Clin Orthop 205 (1986) 299-308
115. Froum S.J., Wallace S.S., Tarnow D.P., and Cho S.C. Effect of platelet-rich plasma on bone growth and osseointegration in human maxillary sinus grafts: three bilateral case reports. Int J Periodontics Restorative Dent 22 1 (2002) 45-53
116. Shanaman R., Filstein M.R., and Danesh-Meyer M.J. Localized ridge augmentation using GBR and platelet-rich plasma: case reports. Int J Periodontics Restorative Dent 21 4 (2001) 345-355
117. Arpornmaeklong P., Kochel M., Depprich R., Kubler N.R., and Wurzler K.K. Influence of platelet-rich plasma (PRP) on osteogenic differentiation of rat bone marrow stromal cells. An in vitro study. Int J Oral Maxillofac Surg 33 1 (2004) 60-70
118. Okuda K., Kawase T., Momose M., Murata M., Saito Y., Suzuki H., et al. Platelet-rich plasma contains high levels of platelet-derived growth factor and transforming growth factor-beta and modulates the proliferation of periodontally related cells in vitro. J Periodontol 74 6 (2003) 849-857
119. Kawase T., Okuda K., Wolff L.F., and Yoshie H. Platelet-rich plasma-derived fibrin clot formation stimulates collagen synthesis in periodontal ligament and osteoblastic cells in vitro. J Periodontol 74 6 (2003) 858-864
120. Man D., Plosker H., and Winland-Brown J.E. The use of autologous platelet-rich plasma (platelet gel) and autologous platelet-poor plasma (fibrin glue) in cosmetic surgery. Plast Reconstr Surg 107 1 (2001) 229-237 Discussion 238-229
121. Mazor Z., Peleg M., Garg A.K., and Luboshitz J. Platelet-rich plasma for bone graft enhancement in sinus floor augmentation with simultaneous implant placement: patient series study. Implant Dent 13 1 (2004) 65-72
122. Kassolis J.D., Rosen P.S., and Reynolds M.A. Alveolar ridge and sinus augmentation utilizing platelet-rich plasma in combination with freeze-dried bone allograft: case series. J Periodontol 71 10 (2000) 1654-1661
123. Aghaloo T.L., Moy P.K., and Freymiller E.G. Evaluation of platelet-rich plasma in combination with anorganic bovine bone in the rabbit cranium: a pilot study. Int J Oral Maxillofac Implants 19 1 (2004) 59-65
124. Kroese-Deutman H.C., Vehof J.W., Spauwen P.H., Stoelinga P.J., and Jansen J.A. Orthotopic bone formation in titanium fiber mesh loaded with platelet-rich plasma and placed in segmental defects. Int J Oral Maxillofac Surg 37 6 (2008) 542-549
125. Fennis J.P., Stoelinga P.J., and Jansen J.A. Mandibular reconstruction: a clinical and radiographic animal study on the use of autogenous scaffolds and platelet-rich plasma. Int J Oral Maxillofac Surg 31 3 (2002) 281-286
126. Fennis J.P., Stoelinga P.J., and Jansen J.A. Mandibular reconstruction: a histological and histomorphometric study on the use of autogenous scaffolds, particulate cortico-cancellous bone grafts and platelet rich plasma in goats. Int J Oral Maxillofac Surg 33 1 (2004) 48-55
127. Okuda K., Tai H., Tanabe K., Suzuki H., Sato T., Kawase T., et al. Platelet-rich plasma combined with a porous hydroxyapatite graft for the treatment of intrabony periodontal defects in humans: a comparative controlled clinical study. J Periodontol 76 6 (2005) 890-898
128. Hanna R., Trejo P.M., and Weltman R.L. Treatment of intrabony defects with bovine-derived xenograft alone and in combination with platelet-rich plasma: a randomized clinical trial. J Periodontol 75 12 (2004) 1668-1677
129. Kitoh H., Kitakoji T., Tsuchiya H., Katoh M., and Ishiguro N. Transplantation of culture expanded bone marrow cells and platelet rich plasma in distraction osteogenesis of the long bones. Bone (2006)
130. Ouyang X.Y., and Qiao J. Effect of platelet-rich plasma in the treatment of periodontal intrabony defects in humans. Chin Med J 119 18 (2006) 1511-1521
131. Piemontese M., Aspriello S.D., Rubini C., Ferrante L., and Procaccini M. Treatment of periodontal intrabony defects with demineralized freeze-dried bone allograft in combination with platelet-rich plasma: a comparative clinical trial. J Periodontol 79 5 (2008) 802-810
132. Nimni M.E. Polypeptide growth factors: targeted delivery systems. Biomaterials 18 18 (1997) 1201-1225
133. Sands J.J., Nudo S.A., Ashford R.G., Moore K.D., and Ortel T.L. Antibodies to topical bovine thrombin correlate with access thrombosis. Am J Kidney Dis 35 5 (2000) 796-801
134. Chouhan V.D., De La Cadena R.A., Nagaswami C., Weisel J.W., Kajani M., and Rao A.K. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function. Thromb Haemost 77 2 (1997) 343-349
135. Christie R.J., Carrington L., and Alving B. Postoperative bleeding induced by topical bovine thrombin: report of two cases. Surgery 121 6 (1997) 708-710
136. Dorion R.P., Hamati H.F., Landis B., Frey C., Heydt D., and Carey D. Risk and clinical significance of developing antibodies induced by topical thrombin preparations. Arch Pathol Lab Med 122 10 (1998) 887-894
137. Israels S.J., and Israels E.D. Development of antibodies to bovine and human factor V in two children after exposure to topical bovine thrombin. Am J Pediatr Hematol Oncol 16 3 (1994) 249-254
138. Lawson J.H. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 32 Suppl. 1 (2006) 98-110
139. Sarfati M.R., Dilorenzo D.J., Kraiss L.W., and Galt S.W. Severe coagulopathy following intraoperative use of topical thrombin. Ann Vasc Surg 18 3 (2004) 349-351
140. Spero J.A. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases. J Neurosurg 78 5 (1993) 817-820
141. Zehnder J.L., and Leung L.L. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 76 10 (1990) 2011-2016
142. Intini G., Andreana S., Margarone III J.E., Bush P.J., and Dziak R. Engineering a bioactive matrix by modifications of calcium sulfate. Tissue Eng 8 6 (2002) 997-1008
143. Bateman J., Intini G., Margarone J., Goodloe S., Bush P., Lynch S.E., et al. Platelet-derived growth factor enhancement of two alloplastic bone matrices. J Periodontol 76 11 (2005) 1833-1841
144. Intini G., Andreana S., Intini F.E., Buhite R.J., and Bobek L.A. Calcium sulfate and platelet-rich plasma make a novel osteoinductive biomaterial for bone regeneration. J Transl Med 5 (2007) 13